ArticleFrontiers in immunology2026

Correction: Effectiveness and safety of rituximab monotherapy versus conventional regimens for adult idiopathic membranous nephropathy: real-world retrospective study.

Frontiers Production OfficePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.